Solving the puzzle of autoimmunity: Critical questions

F1000Prime Reports

Volumn 7, Issue , 2015, Pages

  Smilek, Dawn E ^a   St Clair, E William ^a,b  

^a Immune Tolerance Network   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN;

ADAPTIVE IMMUNITY; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; EPIGENETICS; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; MICROBIOME; NONHUMAN; PATHOGENESIS; PHENOTYPE; RHEUMATOID ARTHRITIS;

EID: 84922359379     PISSN: None     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P7-17     Document Type: Article

References (76)

1. Bluestone JA: Mechanisms oftolerance. ImmunolRev2011,241:5-19.
2. Sherlock JP, Buckley CD, Cua DJ: The critical role of interleukin-23 in spondyloarthropathy. Mol Immunol 2014, 57:38-43.
3. Lowes MA, Suarez-Farinas M, KruegerJG: Immunology of psoriasis. Annu Rev Immunol 2014, 32:227-55.
4. St Clair EW: Novel targeted therapies for autoimmunity. Curr Opin Immunol 2009, 21:648-57.
5. Saxe J: The blind men and the elephant. in The Poems. Washington: Library of Congress, 1873:260. https://archive.org/stream/poemsjohn-godfre02saxegoog#page/n276/mode/2up.
6. Catrina AI, Ytterberg AJ, Reynisdottir G, Malmström V, Klareskog L: Lungs, joints and immunity against citrullinated proteins in rheumatoid arthritis. Nat Rev Rheumatol 2014, 10:645-53.
7. Klareskog L, Stolt P, Lundberg K., Källberg H, Bengtsson C., Grunewald J, Rönnelid J, Harris H.E., Ulfgren AK, Rantapää-Dahlqvist S, Eklund A, Padyukov L, Alfredsson L: A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006, 54:38-46.
8. Klareskog L, Malmström V, Lundberg K., Padyukov L, Alfredsson L: Smoking, citrullination and genetic variability in the immuno-pathogenesis of rheumatoid arthritis. Semin Immunol 2011, 23:92-8.
9. Nielen M, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP, Dijkmans BA: Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004, 50:380-6.
10. Perry E, Kelly C, Eggleton P., De Soyza A, Hutchinson D: The lung in ACPA-positive rheumatoid arthritis: an initiating site of injury? Rheumatology (Oxford) 2014, 53:1940-50.
11. Scher JU, Bretz WA, Abramson SB: Periodontal disease and sublingual microbiota as contributors for rheumatoid arthritis pathogenesis: modifiable risk factors? Curr Opin Rheumatol 2014, 26:424-9.
12. Ytterberg AJ, Joshua V, Reynisdottir G., Tarasova NK, Rutishauser D, Ossipova E, Haj Hensvold A, Eklund A, Sköld CM, Grunewald J., Malmström V, Jakobsson PJ, Rönnelid J, Padyukov L, Zubarev RA, Klareskog L, Catrina AI: Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation. Ann Rheum Dis 2014.
13. Romero V, Fert-Bober J, Nigrovic P.A., Darrah E., Haque UJ, Lee DM, van Eyk J, Rosen A, Andrade F: Immune-mediated pore-forming pathways induce cellular hypercitrullination and generate citrullinated autoantigens in rheumatoid arthritis. Sci Transl Med 2013, 5:209ra150.
14. Snir O, Widhe M, Hermansson M., von Spee C, Lindberg J, Hensen S., Lundberg K, Engström A, Venables P.J., Toes RE, Holmdahl R, Klareskog L, Malmström V: Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum 2010, 62:44-52.
15. Amara K, Steen J, Murray F., Morbach H, Fernandez-Rodriguez BM, Joshua V, Engström M, Snir O., Israelsson L, Catrina AI, Wardemann H, Corti D., Meffre E, Klareskog L, Malmström V: Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition. J Exp Med 2013, 210:445-55.
16. Harre U, Georgess D, Bang H., Bozec A, Axmann R, Ossipova E., Jakobsson PJ, Baum W, Nimmerjahn F, Szarka E., Sarmay G, Krumbholz G, Neumann E, Toes R, Scherer HU, Catrina AI, Klareskog L, Jurdic P, Schett G: Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 2012, 122:1791-802.
17. Kleyer A, Finzel S, Rech J., Manger B, Krieter M, Faustini F., Araujo E, Hueber AJ, Harre U, Engelke K., Schett G: Bone loss before the clinical onset of rheumatoid arthritis in subjects with antici-trullinated protein antibodies. Ann Rheum Dis 2014, 73:854-60.
18. Sokolove J, Zhao X, Chandra P.E., Robinson WH: Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcgamma receptor. Arthritis Rheum 2011, 63:53-62.
19. Yoshida K, Korchynskyi O, Tak P.P., Isozaki T., Ruth JH, Campbell PL, Baeten DL, Gerlag D.M., Amin MA, Koch AE: Citrullination of ENA-78/CXCL5 results in conversion from a non-monocyte recruiting to a monocyte recruiting chemokine. Arthritis Rheumatol 2014, 66:2716-27.
20. Brink M, Hansson M, Mathsson L., Jakobsson PJ, Holmdahl R, Hallmans G, Stenlund H., Rönnelid J, Klareskog L., Rantapää-Dahlqvist S: Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis Rheum 2013, 65:899-910.
21. Eriksson C, Kokkonen H, Johansson M., Hallmans G, Wadell G, Rantapää-Dahlqvist S: Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res Ther 2011, 13:R30.
22. Deane KD, O'Donnell CI, Hueber W, Majka D.S., Lazar AA, Derber LA, Gilliland WR, Edison J.D., Norris JM, Robinson WH, Holers VM: The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arthritis Rheum 2010, 62:3161-72.
23. Eriksson C, Rantapaa-Dahlqvist S: Cytokines in relation to autoantibodies before onset of symptoms for systemic lupus erythematosus. Lupus 2014, [Epub ahead of print].
24. Twin studies in autoimmune disease: genetics, gender and environment: Twin studies in autoimmune disease: genetics, gender and environment. J Autoimmun 2012, 38:J156-69.
25. Parks CG, Miller FW, Pollard K.M., Selmi C., Germolec D, Joyce K, Rose N.R., Humble M: Expert panel workshop consensus statement on the role of the environment in the development of autoimmune disease. Int J Mol Sci 2014, 15:14269-97.
26. Richardson BC, Patel DR: Epigenetics in 2013. DNA methylation and miRNA-key roles in systemic autoimmunity. Nat Rev Rheumatol 2014, 10:72-4.
27. Somers EC, Richardson BC: Environmental exposures, epigenetic changes and the risk of lupus. Lupus 2014, 23:568-76.
28. Richardson B: Primer: epigenetics of autoimmunity. Nat Clin Pract Rheumatol 2007, 3:521-7.
29. Li Y, Gorelik G, Strickland F.M., Richardson BC: Oxidative stress, T cell DNA methylation, and lupus. Arthritis Rheumatol 2014, 66:1574-82.
30. Ivanov II, Honda K: Intestinal commensal microbes as immune modulators. Cell Host Microbe 2012, 12:496-508.
31. Hooper LV, Littman DR, Macpherson AJ: Interactions between the microbiota and the immune system. Science 2012, 336:1268-73.
32. Ivanov II, Atarashi K, Manel N., Brodie EL, Shima T, Karaoz U, Wei D., Goldfarb KC, Santee CA, Lynch SV, Tanoue T, Imaoka A., Itoh K, Takeda K, Umesaki Y, Honda K, Littman DR: Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009, 139:485-98.
33. Singh RP, Hasan S, Sharma S., Nagra S, Yamaguchi DT, Wong D.T., Hahn BH, Hossain A: Th17 cells in inflammation and autoimmunity. Autoimmun Rev 2014, 13:1174-81.
34. Wu HJ, Ivanov II, Darce J, Hattori K., Shima T, Umesaki Y, Littman D.R., Benoist C., Mathis D: Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 2010, 32:815-27.
35. Lee YK, Menezes JS, Umesaki Y, Mazmanian SK: Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2011, 108(SUPPL. 1):4615-22.
36. Scher JU, Sczesnak A, Longman R.S., Segata N., Ubeda C, Bielski C, Rostron T., Cerundolo V, Pamer EG, Abramson S.B., Huttenhower C., Littman DR: Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife 2013, 2:e01202.
37. Goodnow CC1, Sprent J, Fazekas de St Groth B, Vinuesa CG: Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 2005, 435:590-7.
38. Abreu JR, Martina S, Verrijn Stuart AA, Fillié YE, Franken KL, Drijfhout JW, Roep BO: CD8 T cell autoreactivity to pre-proinsulin epitopes with very lowhuman leucocyte antigen class I binding affinity. Clin Exp Immunol 2012, 170:57-65.
39. Yang J, Chow IT, Sosinowski T, Torres-Chinn N, Greenbaum C.J., James EA, Kappler JW, Davidson HW, Kwok W: Autoreactive T cells specific for insulin B:11-23 recognize a low-affinity peptide register in human subjects with autoimmune diabetes. Proc Natl Acad Sci USA 2014, 111:14840-14845.
40. Clayton GM, Wang Y, Crawford F., Novikov A, Wimberly BT, Kieft J.S., Falta MT, Bowerman NA, Marrack P, Fontenot A.P., Dai S., Kappler JW: Structural basis of chronic beryllium disease: linking allergic hypersensitivity and autoimmunity. Cell 2014, 158:132-42.
41. Tsai S, Santamaria P: MHC class II polymorphisms, autoreactive T-cells, and autoimmunity. Front Immunol 2013, 4:1-7.
42. Alvarez-Navarro C, Cragnolini JJ, Dos Santos HG, Barnea E, Admon A, Morreale A., López de Castro JA: Novel HLA-B27-restricted epitopes from Chlamydia trachomatis generated upon endogenous processing of bacterial proteins suggest a role of molecular mimicry in reactive arthritis. J Biol Chem 2013, 288:25810-25.
43. Turner MJ, Delay ML, Bai S, Klenk E., Colbert RA: HLA-B27 up-regulation causes accumulation of misfolded heavy chains and correlates with the magnitude of the unfolded protein response in transgenic rats. Arthritis Rheum 2007, 56:215-23.
44. Colbert RA, Tran TM, Layh-Schmitt G: HLA-B27 misfolding and ankylosing spondylitis. Mol Immunol 2014, 57:44-51.
45. Parkes M, Cortes A, van Heel DA, Brown MA: Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat Rev Genet 2013, 14:661-73.
46. Cho JH, Gregersen PK: Genomics and the multifactorial nature of human autoimmune disease. N Engl J Med 2011, 365:1612-23.
47. Nagamine K, Peterson P, Scott H.S., Kudoh J., Minoshima S, Heino M, Krohn K.J., Lalioti MD, Mullis PE, Antonarakis SE, Kawasaki K, Asakawa S., Ito F, Shimizu N: Positional cloning of the APECED gene. Nat Genet 1997, 17:393-8.
48. Anderson MS1, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ, von Boehmer H, Bronson R, Dierich A, Benoist C, Mathis D: Projection of an immunological self shadow within the thymus by the aire protein. Science 2002, 298:1395-401.
49. Anderson MS, Su MA: Aire and T cell development. Curr Opin Immunol 2011, 23:198-206.
50. Hunt KA, Mistry V, Bockett N.A., Ahmad T., Ban M, Barker JN, Barrett J.C., Blackburn H., Brand O, Burren O, Capon F., Compston A, Gough SC, Jostins L, Kong Y, Lee JC, Lek M, MacArthur DG, Mansfield JC, Mathew CG, Mein CA, Mirza M, Nutland S, Onengut-Gumuscu S, Papouli E, Parkes M, Rich SS, Sawcer S, Satsangi J, Simmonds MJ, Trembath RC, Walker NM, Wozniak E, Todd JA, Simpson MA, Plagnol V, van Heel DA: Negligible impact of rare autoimmune-locus coding-region variants on missing herit-ability. Nature 2013, 498:232-5.
51. Surolia I, Pirnie SP, Chellappa V, Taylor K.N., Cariappa A., Moya J, Liu H, Bell D.W., Driscoll DR, Diederichs S, Haider K, Netravali I., Le S, Elia R, Dow E, Lee A, Freudenberg J, De Jager PL, Chretien Y, Varki A, MacDonald ME, Gillis T, Behrens TW, Bloch D, Collier D, Korzenik J, Podolsky DK, Hafler D, Murali M, Sands B, Stone JH, Gregersen PK, Pillai S: Functionally defedtive germline variants of sialic acid acetylesterase in autoimmunity. Nature 2010, 466:243-7.
52. Cárdenas-Roldán J, Rojas-Villarraga A, Anaya JM: How do autoimmune diseases cluster in families? A systematic review and meta-analysis. BMC Med 2013, 11:73.
53. Begovich AB, Carlton VE, Honigberg L.A., Schrodi SJ, Chokkalingam AP, Alexander HC, Ardlie K.G., Huang Q., Smith AM, Spoerke JM, Conn MT, Chang M, Chang S.Y., Saiki RK, Catanese JJ, Leong DU, Garcia VE, McAllister LB, Jeffery DA, Lee AT, Batliwalla F, Remmers E, Criswell LA, Seldin MF, Kastner DL, Amos CI, Sninsky JJ, Gregersen PK: A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004, 75:330-7.
54. Kyogoku C, Langefeld CD, Ortmann W.A., Lee A., Selby S, Carlton VE, Chang M, Ramos P., Baechler EC, Batliwalla FM, Novitzke J, Williams A.H., Gillett C., Rodine P, Graham RR, Ardlie KG, Gaffney PM, Moser KL, Petri M, Begovich AB, Gregersen PK, Behrens TW: Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet 2004, 75:504-7.
55. Criswell LA, Pfeiffer KA, Lum R.F., Gonzales B., Novitzke J, Kern M, Moser K.L., Begovich AB, Carlton VE, Li W, Lee A.T., Ortmann W., Behrens TW, Gregersen PK: Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am J Hum Genet 2005, 76:561-71.
56. Stanford SM, Bottini N: PTPN22: the archetypal non-HLA autoimmunity gene. Nat Rev Rheumatol 2014, 10:602-11.
57. Rieck M, Arechiga A, Onengut-Gumuscu S, Greenbaum C., Concannon P, Buckner JH: Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol 2007, 179:4704-10.
58. Zhang J, Zahir N, Jiang Q., Miliotis H, Heyraud S, Meng X., Dong B, Xie G, Qiu F., Hao Z, McCulloch CA, Keystone EC, Peterson AC, Siminovitch KA: The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperrespon-siveness. Nat Genet 2011, 43:902-7.
59. Menard L, Saadoun D, Isnardi I., Ng YS, Meyers G, Massad C, Price C., Abraham C, Motaghedi R, Buckner J.H., Gregersen PK, Meffre E: The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J Clin Invest 2011, 121:3635-44.
60. Habib T, Funk A, Rieck M., Brahmandam A, Dai X, Panigrahi A.K., Luning Prak ET, Meyer-Bahlburg A, Sanda S, Greenbaum C., Rawlings DJ, Buckner JH: Altered B cell homeostasis is associated with type I diabetes and carriers of the PTPN22 allelic variant. J Immunol 2012, 188:487-96.
61. Nepom GT, Buckner JH: A functional framework for interpretation of genetic associations in T1D. Curr Opin Immunol 2012, 24:516-21.
62. Wang Y, Shaked I, Stanford S.M., Zhou W., Curtsinger JM, Mikulski Z, Shaheen ZR, Cheng G, Sawatzke K., Campbell AM, Auger JL, Bilgic H, Shoyama F.M., Schmeling DO, Balfour HH Jr, Hasegawa K, Chan AC, Corbett JA, Binstadt BA, Mescher MF, Ley K, Bottini N, Peterson EJ: The autoimmunity-associated gene PTPN22 potentiates tolllike receptor-driven, type 1 interferon-dependent immunity. Immunity 2013, 39:111-22.
63. Duerr RH, Taylor KD, Brant S.R., Rioux JD, Silverberg MS, Daly MJ, Steinhart A.H., Abraham C., Regueiro M, Griffiths A, Dassopoulos T., Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH: A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006, 314:1461-3.
64. Cargill M, Schrodi SJ, Chang M, Garcia V.E., Brandon R., Callis KP, Matsunami N, Ardlie KG, Civello D, Catanese J.J., Leong DU, Panko JM, McAllister LB, Hansen C.B., Papenfuss J., Prescott SM, White TJ, Leppert MF, Krueger GG, Begovich AB: A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007, 80:273-90.
65. Kenna TJ, Brown MA: The role of IL-17-secreting mast cells in inflammatory joint disease. Nat Rev Rheumatol 2013, 9:375-9.
66. Schett G, Elewaut D, McInnes I.B., Dayer JM, Neurath M: How cytokine networks fuel inflammation: Toward acytokine-based 6disease taxonomy. Nat Med 2013, 19:822-4.
67. Gregory AP, Dendrou CA, Attfield K.E., Haghikia A., Xifara DK, Butter F, Poschmann G, Kaur G., Lambert L, Leach OA, Prömel S, Punwani D., Felce JH, Davis SJ, Gold R, Nielsen FC, Siegel RM, Mann M, Bell JI, McVean G, Fugger L: TNF receptor 1 genetic risk mirrors outcome ofanti-TNF therapy in multiple sclerosis. Nature2012,488:508-11.
68. Bosch X, Saiz A, Ramos-Casals M; BIOGEAS Study Group: Monoclonal antibody therapy-associated neurological disorders. Nature Rev Neurol 2011, 7:165-72.
69. Comabella M, Lünemann JD, Río J, Sánchez A, López C, Julià E, Fernández M, Nonell L, Camiña-Tato M, Deisenhammer F, Caballero E, Tortola MT, Prinz M, Montalban X, Martin R: A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 2009, 132:3353-65.
70. Hundeshagen A, Hecker M, Paap B.K., Angerstein C., Kandulski O, Fatum C, Hartmann C., Koczan D, Thiesen HJ, Zettl UK: Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance. J Neuroinflammation 2012, 9:140.
71. Axtell RC, Raman C, Steinman L: Type I interferons: beneficial in Th1 and detrimental in Th17 autoimmunity. Clin Rev Allergy Immunol 2013, 44:114-20.
72. Vosslamber S, Raterman HG, van der Pouw Kraan TC, Schreurs MW, von Blomberg BM, Nurmohamed MT, Lems WF, Dijkmans BA, Voskuyl AE, Verweij CL: Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. Ann Rheum Dis 2011, 70:1153-9.
73. Raterman HG, Vosslamber S, de Ridder S, Nurmohamed MT, Lems W.F., Boers M., van de Wiel M, Dijkmans BA, Verweij CL, Voskuyl A: The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther 2012, 14:R95.
74. Sellam J, Marion-Thore S, Dumont F., Jacques S, Garchon HJ, Rouanet S, Taoufik Y., Hendel-Chavez H, Sibilia J, Tebib J., Le Loët X, Combe B, Dougados M, Mariette X, Chiocchia G: Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial. Arthritis Rheumatol 2014, 66:2015-25.
75. Chan AC, Behrens TW: Personalizing medicine for autoimmune and inflammatory diseases. Nat Immunol 2013, 14:106-9.
76. Smilek DE, Ehlers MR, Nepom GT: Restoring the balance: immunotherapeutic combinations for autoimmune disease. Dis Model Mech 2014, 7:503-13.